Lung cancer in Brazil: epidemiology and treatment challenges

IF 5.1 Q1 ONCOLOGY Lung Cancer: Targets and Therapy Pub Date : 2016-11-14 DOI:10.2147/LCTT.S93604
V. D. de Sá, J. Coelho, V. Capelozzi, Sergio Jobim de Azevedo
{"title":"Lung cancer in Brazil: epidemiology and treatment challenges","authors":"V. D. de Sá, J. Coelho, V. Capelozzi, Sergio Jobim de Azevedo","doi":"10.2147/LCTT.S93604","DOIUrl":null,"url":null,"abstract":"Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women (fourth most common). These data are consistent for all Brazilian regions and reflect the trends of cancer in the country over the last decade. Brazil is a continental country, the largest in Latin America and fifth in the world, with an estimated population of >200 million. Although the discrepancy in the national income between rich and poor has diminished in the last 2 decades, it is still huge. More than 75% of the Brazilian population do not have private health insurance and rely on the national health care system, where differences in standard of cancer care are evident. It is possible to point out differences from the recommendations of international guidelines in every step of the lung cancer care, from the diagnosis to the treatment of advanced disease. This review aims to describe and recognize these differences as a way to offer a real discussion for future modifications and action points toward delivery of better oncology care in our country.","PeriodicalId":18066,"journal":{"name":"Lung Cancer: Targets and Therapy","volume":"28 1","pages":"141 - 148"},"PeriodicalIF":5.1000,"publicationDate":"2016-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"25","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer: Targets and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/LCTT.S93604","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 25

Abstract

Lung cancer persists throughout the world as a major cause of death. In 2014, data from the Brazilian National Cancer Institute (INCA) estimated 16.400 new cases of lung cancer among men (second most common) and 10.930 new cases among women (fourth most common). These data are consistent for all Brazilian regions and reflect the trends of cancer in the country over the last decade. Brazil is a continental country, the largest in Latin America and fifth in the world, with an estimated population of >200 million. Although the discrepancy in the national income between rich and poor has diminished in the last 2 decades, it is still huge. More than 75% of the Brazilian population do not have private health insurance and rely on the national health care system, where differences in standard of cancer care are evident. It is possible to point out differences from the recommendations of international guidelines in every step of the lung cancer care, from the diagnosis to the treatment of advanced disease. This review aims to describe and recognize these differences as a way to offer a real discussion for future modifications and action points toward delivery of better oncology care in our country.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
巴西的肺癌:流行病学和治疗挑战
肺癌仍然是世界各地的一个主要死亡原因。2014年,巴西国家癌症研究所(INCA)的数据估计,男性中有16400例新发肺癌病例(第二常见),女性中有10930例新发病例(第四常见)。这些数据在巴西所有地区都是一致的,反映了过去十年来该国癌症的趋势。巴西是一个大陆国家,是拉丁美洲最大、世界第五大国,人口估计超过2亿。尽管在过去20年里,贫富之间的国民收入差距已经缩小,但差距仍然很大。超过75%的巴西人口没有私人医疗保险,依赖国家卫生保健系统,其中癌症治疗标准的差异是显而易见的。在肺癌护理的每一步,从诊断到晚期疾病的治疗,都可以指出与国际指南建议的差异。这篇综述的目的是描述和认识这些差异,为未来的修改和行动点提供一个真正的讨论,以提供更好的肿瘤治疗在我国。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.10
自引率
0.00%
发文量
10
审稿时长
16 weeks
期刊最新文献
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea. Adagrasib in KRYSTAL-12 has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma. NRG1 Fusions in NSCLC: Being eNRGy Conscious. Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature. Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1